MBX Biosciences, Inc. (MBX) Financial Statements
Free cash flow over the same period: -$85.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MBXMBX Biosciences, Inc.Follow MBX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 57.4 | 79.2 | 88.5 | |
| Operating income | -68.2 | -98.1 | -117.9 | |
| Pre-tax income | -61.9 | -87.0 | -104.3 | |
| Income tax | 0.0 | 0.0 | — | |
| Net income | -61.9 | -87.0 | -104.3 | |
| Diluted EPS ($) | -5.82 | -2.38 | -2.18 | |
| Diluted shares (mn) | 10.6 | 36.5 | — |
USD millions · SEC XBRL
MBX Biosciences, Inc. — questions
- What is MBX Biosciences, Inc.'s net income?
- -$104.3M over the twelve months to 2026-06-30.
- What is MBX Biosciences, Inc.'s free cash flow?
- -$85.2M over the twelve months to 2026-06-30.
- What are MBX Biosciences, Inc.'s diluted earnings per share?
- $-2.18 over the twelve months to 2026-06-30.
Every figure on this page comes from MBX Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.